UK Fails To Fund Asbestos Group for Mesothelioma ResearchTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Whitmer, M. (2022, February 2). UK Fails To Fund Asbestos Group for Mesothelioma Research. Asbestos.com. Retrieved October 6, 2022, from https://www.asbestos.com/news/2011/02/11/mesothelioma-developments-underway-despite-loss-of-funding/
Whitmer, Michelle. "UK Fails To Fund Asbestos Group for Mesothelioma Research." Asbestos.com, 2 Feb 2022, https://www.asbestos.com/news/2011/02/11/mesothelioma-developments-underway-despite-loss-of-funding/.
Whitmer, Michelle. "UK Fails To Fund Asbestos Group for Mesothelioma Research." Asbestos.com. Last modified February 2, 2022. https://www.asbestos.com/news/2011/02/11/mesothelioma-developments-underway-despite-loss-of-funding/.
The search for a mesothelioma cure is still underway, and a number of medical researchers are dedicating their time to extensive clinical and laboratory tests in hopes of eradicating this rare cancer.
While many promising developments have been made to fight the disease, adequate funding for future projects must be secured to ensure further progress.
Caused almost exclusively by asbestos exposure, asbestos cancer claims 2,000 to 3,000 lives a year in the United States alone. Since no known cure currently exists, further research is undoubtedly necessary. Unfortunately, one major source of funding for research in the United Kingdom failed to follow through on a 2010 promise to invest money into research by creating a National Centre for Asbestos Related Disease (NCARD).
When asked how much money would be provided for research over the next three years, health minister Simon Burns simply stated that the National Institute for Health Research and the Medical Research Council was still accepting applications for funding. No mention was made of NCARD or the Government’s prior commitment to help launch the organization.
The union then questioned the coalition Government’s estimated importance of the disease. With a prognosis of less than 10 months after diagnosis in the United Kingdom, more effective treatment options are certainly necessary to improve the life expectancy associated with mesothelioma.
While advocates continue to secure funding for further research, patients can contribute to research by participating in clinical trials that test potential new drugs and procedures.
Before a new treatment can be approved for widespread use, the therapy in question must be tested and shown to have a safe and significant affect on human patients. Clinical studies to assess treatment options are typically sponsored at a hospital or cancer center and are performed under strict guidelines. Immunotherapy and photodynamic therapy are two treatments that have been recently introduced after promising results were recorded during clinical trials.
Doctors and oncologists are better able to treat their patients after studying new breakthroughs in the field. In 2002, 9 percent of patients survived for five years after diagnosis in the United States. The U.S. five-year survival rate has currently increased to 10 percent of patients. Furthermore, in the 1990s, patients rarely lived a year after diagnosis, while now around 40 percent survive for a year or more in the United States. Doctors hope that medical advancement s can continue to improve the global mesothelioma survival rate in the years to come.